Pub. Date : 2017 Jan
PMID : 27766434
12 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | MG132 plus apoptosis antigen-1 (APO-1) antibody cooperate to restore p53 activity inducing autophagy and p53-dependent apoptosis in HPV16 E6-expressing keratinocytes. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 2 | MG132 plus apoptosis antigen-1 (APO-1) antibody cooperate to restore p53 activity inducing autophagy and p53-dependent apoptosis in HPV16 E6-expressing keratinocytes. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 3 | We investigated whether in HPV16 E6-expressing keratinocytes (KE6 cells), the restoration of p53 levels mediated by MG132 and/or activation of the CD95 pathway through apoptosis antigen-1 (APO-1) antibody are responsible for the induction of apoptosis. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 4 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 5 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 6 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 7 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 8 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 9 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 10 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 11 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |
| 12 | Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | tumor protein p53 | Homo sapiens |